KalVista Pharmaceuticals (STU:4XC1) Change In Payables And Accrued Expense : €6.65 Mil (TTM As of Jan. 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Change In Payables And Accrued Expense?

KalVista Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Jan. 2024 was €0.85 Mil. It means KalVista Pharmaceuticals's Accounts Payable & Accrued Expense increased by €0.85 Mil from Oct. 2023 to Jan. 2024 .

KalVista Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Apr. 2023 was €2.77 Mil. It means KalVista Pharmaceuticals's Accounts Payable & Accrued Expense increased by €2.77 Mil from Apr. 2022 to Apr. 2023 .

KalVista Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for KalVista Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Change In Payables And Accrued Expense Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

3.74

-0.97

0.95

2.00

2.77

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-0.11	2.96	-1.02	3.85	0.85

KalVista Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.65 Mil.

KalVista Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (STU:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (STU:4XC1) Headlines

No Headlines